Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

86 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular morbidity over 10years in the CLARICOR randomised, blinded clinical trial.
Winkel P, Hilden J, Hansen JF, Kastrup J, Kolmos HJ, Kjøller E, Jensen GB, Skoog M, Lindschou J, Gluud C; CLARICOR trial group. Winkel P, et al. Among authors: kjoller e. Int J Cardiol. 2015 Mar 1;182:459-65. doi: 10.1016/j.ijcard.2015.01.020. Epub 2015 Jan 6. Int J Cardiol. 2015. PMID: 25602299 Clinical Trial.
High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease.
Kastrup J, Johansen JS, Winkel P, Hansen JF, Hildebrandt P, Jensen GB, Jespersen CM, Kjøller E, Kolmos HJ, Lind I, Nielsen H, Gluud C; CLARICOR Trial Group. Kastrup J, et al. Among authors: kjoller e. Eur Heart J. 2009 May;30(9):1066-72. doi: 10.1093/eurheartj/ehp049. Epub 2009 Mar 6. Eur Heart J. 2009. PMID: 19270316 Free article. Clinical Trial.
Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart disease.
Jensen GB, Hilden J, Als-Nielsen B, Damgaard M, Hansen JF, Hansen S, Helø OH, Hildebrandt P, Kastrup J, Kolmos HJ, Kjøller E, Lind I, Nielsen H, Petersen L, Jespersen CM, Gluud C; CLARICOR Trial Group. Jensen GB, et al. Among authors: kjoller e. J Cardiovasc Pharmacol. 2010 Feb;55(2):123-8. doi: 10.1097/FJC.0b013e3181c87e37. J Cardiovasc Pharmacol. 2010. PMID: 19920766 Clinical Trial.
Chlamydia pneumoniae IgG and IgA antibody titers and prognosis in patients with coronary heart disease: results from the CLARICOR trial.
Hilden J, Lind I, Kolmos HJ, Als-Nielsen B, Damgaard M, Hansen JF, Hansen S, Helø OH, Hildebrandt P, Jensen GB, Kastrup J, Kjøller E, Nielsen H, Petersen L, Jespersen CM, Gluud C; CLARICOR Trial Group. Hilden J, et al. Among authors: kjoller e. Diagn Microbiol Infect Dis. 2010 Apr;66(4):385-92. doi: 10.1016/j.diagmicrobio.2009.11.011. Diagn Microbiol Infect Dis. 2010. PMID: 20226329 Clinical Trial.
High-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide in patients with stable coronary artery disease: a prognostic study within the CLARICOR trial.
Harutyunyan MJ, Mathiasen AB, Winkel P, Gøtze JP, Hansen JF, Hildebrandt P, Jensen GB, Hilden J, Jespersen CM, Kjøller E, Kolmos HJ, Gluud C, Kastrup J; CLARICOR Trial Group. Harutyunyan MJ, et al. Among authors: kjoller e. Scand J Clin Lab Invest. 2011 Feb;71(1):52-62. doi: 10.3109/00365513.2010.538081. Epub 2010 Nov 25. Scand J Clin Lab Invest. 2011. PMID: 21108561 Clinical Trial.
Risk stratification in stable coronary artery disease is possible at cardiac troponin levels below conventional detection and is improved by use of N-terminal pro-B-type natriuretic peptide.
Lyngbæk S, Winkel P, Gøtze JP, Kastrup J, Gluud C, Kolmos HJ, Kjøller E, Jensen GB, Hansen JF, Hildebrandt P, Hilden J; CLARICOR Trial Group. Lyngbæk S, et al. Among authors: kjoller e. Eur J Prev Cardiol. 2014 Oct;21(10):1275-84. doi: 10.1177/2047487313492099. Epub 2013 May 30. Eur J Prev Cardiol. 2014. PMID: 23723326 Clinical Trial.
86 results